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ABSTRACT OF DISSERTATION

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ARE ANTIINFLAMMATORY AND TARGET DRY AGE-RELATED MACULAR
DEGENERATION
Inflammation driven by the NLRP3 inflammasome induces retinal pigment
epithelium (RPE) cell death in dry age-related macular degeneration (AMD), a
devastating and currently untreatable blindness that affects tens of millions of
people worldwide. In the dry AMD model based on Alu RNA accumulation in the
RPE, cytotoxic non-coding Alu RNAs cause macular degeneration. Although the
precise molecular details of how Alu RNAs induce inflammasome activation are
not fully understood, it is known that Alu RNA requires endogenous reverse
transcriptase (LINE-1) for its life cycle. Therefore, we hypothesized that
nucleoside reverse transcriptase inhibitors (NRTIs) block inflammasome
activation and RPE cell death in cell culture and animal models of dry AMD.
Here, we have identified a novel anti-inflammatory action of NRTIs characterized
by P2X7 and NLRP3 inflammasome inhibition, and demonstrated their in vivo
ability to prevent RPE cell death in a mouse model of dry AMD. The tested NRTI
compounds have been FDA-approved and widely used clinically for decades, and
are therefore ideal drug repurposing candidates in an unanticipated treatment
strategy for dry AMD.
KEYWORDS: Nucleoside reverse transcriptase inhibitors, age-related macular
degeneration, NLRP3 inflammasome, P2X7, Alu RNA
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Chapter 1: Introduction
1.1

General Background
Sections 1.1.1 through 1.4 are copied in part, and adapted, from my pre-published
work 1.
1.1.1

Age-related macular degeneration

Age-related macular degeneration (AMD) is a principal cause of blindness in the
United States and other industrialized nations. An estimated 10 million Americans are
afflicted with AMD 2, which is comparable in scope to the 12 million living with cancer
3

, or the 5 million with Alzheimer’s disease 4. The prevalence of AMD steadily increases

with age, affecting 2% of the population at age 40, and one in four people by age 80 2.
For reasons that are not fully understood, AMD is more common in lightly-pigmented
and female populations 2. Treatment of AMD is largely an unmet need: There are no
FDA approved therapies except for a small percentage of individuals with end-stage
disease.
There are two types of AMD, the “dry” and “wet” forms. Dry AMD is a chronic
disease that usually causes some degree of visual impairment, and sometimes progresses
to severe blindness. In contrast, wet AMD affects only 10-15% of AMD patients,
emerges abruptly, and rapidly progresses to blindness if left untreated 5,6. Since AMD
patients typically develop the dry form first, wet AMD occurs on a background of dry
AMD; as such, dry AMD can be considered a risk factor or even precursor state for wet
AMD.
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In the early stages of AMD, which is asymptomatic, insoluble extracellular
aggregates called drusen accumulate in the retina (See Fig. 1 in 7). The late stage of dry
AMD, which is also known as geographic atrophy (GA), is characterized by scattered or
confluent areas of degeneration of retinal pigment epithelium (RPE) cells and the
overlying light-sensing retinal photoreceptors, which rely on the RPE for trophic support.
The other late stage form of AMD, the wet form, is typified by choroidal
neovascularization (CNV) wherein newly immature blood vessels grow towards the outer
retina from the underlying choroid. These immature blood vessels leak fluid below or
within the retina.
It is convenient to dichotomize the pathology of “wet” and “dry” forms of the
disease based on the presence or absence, respectively, of CNV. However, as an
understanding of AMD pathogenesis improves, emerging evidence indicates that
significant overlap exists in the underlying mechanisms of these seemingly disparate
clinical conditions. In spite of this apparent overlapping pathophysiology, the two forms
of AMD are indeed somewhat clinically distinct: that is, effective treatment of wet AMD
does not typically ameliorate the dry AMD component. Clearly, further clarification of
the overlapping and unique processes that lead to wet and dry pathology will be essential
for future advances in the prevention and treatment of AMD.
1.2

The Retina
1.2.1

In health

For a review of structural features in the healthy retina vs. the AMD-afflicted
retina, the reader is referred to excellent reviews elsewhere 7,8. The features of a healthy
ocular fundus is shown in Fig. 1.1 A. Relative to the surrounding peripheral retina, the
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macular region has a high density of photoreceptors. As such, the macula subserves
central vision and acuity that enables resolution of fine details, such as edges or borders.
The retina consists of multiple cell layers that form an interdependent anatomical and
metabolic network. Other notable features of the retina include: the selectively permeable
blood-retinal barrier 9, the greatest oxygen consumption per weight of any organ in the
body 10, and immune privilege 11.
1.2.2

In AMD

1.2.2.1 Geographic atrophy
A representative eye with GA is shown in Fig. 1.1 B. AMD primarily affects the
macular region of the retina, with relative sparing of the surrounding peripheral retina.
AMD is defined by confluent regions of drusen, which are multi-component,
heterogeneous aggregates that lie both external and internal to the RPE cells 12,13 (Fig.
1.2). The emergence and “growth” of drusen occurs slowly over years or decades. RPE
cell death and synaptic dysfunction accompany underlying drusen 14, although the causeeffect relationship of drusen and retinal degeneration (which may be reciprocal) is not
fully understood.
1.2.2.2 Choroidal neovascularization
A representative eye with CNV is shown in Fig. 1.1 C. CNV also primarily
affects the macula. If left untreated, it can lead to severe blindness with scarring within
several months. Assessment of CNV is typically made using fluorescein angiography or
optical coherence tomography to measure characteristic lesions with leakage of blood or
plasma proteins from immature choroidal blood vessels.
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Figure 1.1 Fundus photographs in health and in AMD
(A) The ocular fundus of a healthy eye, showing normal pigmentation and retinal blood
vessels. (B) The late-stage dry form of AMD, known as geographic atrophy. Note large
regions of depigmentation, especially in the macular, which is at the center of the image.
(C) In wet AMD, leaky blood vessels from the choroid invade the overlying retina.
Images are from my previous publication1.
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Figure 1.2 Toxic accumulations in dry AMD
Dry AMD is characterized by the accumulation of various types of retinal debris. Image
adapted from my previous publication1.
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1.3

The RPE: At the core of AMD pathogenesis
Whereas the step-wise development of certain maladies (e.g. cancers) is relatively

well-defined 15, no such hallmarks of disease progression have been identified in AMD.
Nonetheless, the literature abounds with various implicated causes of disease. For want of
a comprehensive systems approach, one could navigate the numerous avenues and
permutations by which an ever-growing list of mechanisms contribute to AMD
pathology. Indeed, such an approach has been emphasized in previous reviews 7,8,16-18.
Previously, we published an integrated perspective on the mechanisms underlying AMD
1

.
In general, although inter-individual heterogeneity exists, RPE dysfunction and

atrophy precedes the latter stages of AMD (GA or CNV). As such, most model systems
in AMD focus on the RPE as the fulcrum of AMD pathogenesis. The RPE integrates
numerous stimuli to define its own health, while also receiving and broadcasting signals
to and from the retinal microenvironment. The capacity of the RPE to modulate diverse
pathways of AMD pathogenesis can be gleaned from RNA transcriptome analyses of
human AMD donor eyes 19,20 and in vitro RPE cells 21. Genome-wide stress-response
transcriptome and proteome assays have begun to catalog the effect of specific AMDassociated stresses 22, and age-related changes in retinal molecular composition 23,24 on
whole-genome RPE gene expression. Although the vitality of the RPE cell is paramount
to retinal health, it is also true that perturbations in other tissues, for example, the
choroid, Bruch’s membrane and photoreceptors, are important burdens on the retinal
microenvironment. Nevertheless, the critical event in AMD pathogenesis, from which
there is no return, is RPE dysfunction and degeneration.
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1.4

Dicer/Alu RNA model of geographic atrophy (GA)
Our laboratory pioneered a mouse model of geographic atrophy (GA) based on

the accumulation of toxic non-coding RNAs called Alu RNAs in the RPE. We found that
DICER1, a ribonuclease, was specifically reduced in the RPE of late stage dry AMD
(GA) patients 25; moreover, this pathological decrease in DICER1 was accompanied by
the aberrant overabundance of the non-coding Alu RNA, which is toxic to RPE cells. In
that study, we presented several experimental approaches to model GA in mice: the
genetic ablation or knockdown of DICER1 in the mouse RPE, or, as will be utilized in
this dissertation, the administration of synthetic Alu RNAs.
The Alu RNAs that accumulate in DICER1 deficiency are transcribed from Alu
DNA sequences in the nuclear genome. Sometimes described as “genomic parasites”,
these ~300 nt DNA sequences constitute at least 11% of all genomic DNA 26. Alus are
retrotransposons, meaning they “jump” around the genome by 1) Transcription; 2)
Reverse transcription; and 3) Genomic integration at a new locus. The deleterious effect
of Alu sequences is often ascribed to a single retrotransposition event; for example, an
Alu sequence may insert into a critical gene, thereby disrupting gene function 27. The
relevance of reverse transcription to the Alu-induced model of GA will be tested in part
and discussed throughout this dissertation.
1.4.1

NLRP3 inflammasome in GA

Recent work from our group has identified an innate immune complex called the
NLRP3 inflammasome as the response platform that mediates Alu RNA-induced RPE
cell death 28. The NLRP3 inflammasome is a complex of three proteins (NLRP3, ASC,
Caspase-1) that is best known for its role in maturing bioactive interleukin-1 beta and -
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18, which allows for their release from cells (Fig. 1.3) 29. In our study we provided
evidence of inflammasome activation in the RPE of human GA donor eyes, and showed
that in experimental DICER1 deficit, activation of the NLRP3 inflammasome by Alu
RNA leads to RPE IL-18 secretion, which induces MyD88-dependent RPE cell death.
This finding helps solidify the central role of the RPE in AMD pathogenesis.
Interestingly, to date, NLRP3 inflammasome activation is almost exclusively confined to
immune cells, thereby presenting an identity crisis for the RPE, which can now be redefined, in part, in terms of its immune function. As will be discussed in section 2.4.1, the
NLRP3 inflammasome appears to be a convergent integrator of multiple AMD-related
stressors (not just Alu RNAs).
1.4.2

Unresolved mechanisms of Alu toxicity

The mechanism of Alu RNA-induced toxicity is depicted in Fig. 1.3 (adapted
from 28) and is based on the findings from three works of our laboratory 28,30,31. The most
upstream molecular player involved in Alu-induced inflammasome activation is the cellsurface ATP receptor P2X7. However, the molecular details that connect Alu RNA
overabundance to P2X7 activation remain unclear.
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Figure 1.3 Mechanism of Alu-induced RPE cell death
Alu RNA activates P2X7 to induce mitochondrial reactive oxygen species-mediated
priming (increased transcription) of NLRP3 and interleukin mRNAs. Alu RNA also
induces formation of the inflammasome complex, which processes interleukins to their
mature form. Alu-induces RPE cell death via MyD88 and phosphorylation of IRAK1/4.
Adapted from 28.

1.5

Scope of thesis
The best-known function of cytotoxic Alu RNAs is invasion of and replication

within the genome. In this natural life cycle of Alu RNAs, genomic Alu sequences are
transcribed into Alu RNA, and the Alu RNA is copied and inserted back into the genome
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via a reverse transcriptase-dependent mechanism (Fig. 2.1). We hypothesized that the life
cycle of Alu RNA is an important mechanistic step that links its accumulation to RPE cell
death and inflammation, and that interference with the Alu life cycle using reverse
transcriptase inhibitors would block these Alu-induced effects. Thus we set out to test
whether nucleoside (analog) reverse transcriptase inhibitors (NRTIs) are protective in the
Alu-induced model of AMD, and also, more broadly, whether these compounds are
inhibitors of the NLRP3 inflammasome and P2X7 in other non-Alu-based experimental
systems. As will be shown, our hypothesis that the Alu RNA life cycle is connected to
RPE death was not correct: Even though NRTIs were protective and blocked RPE cell
death when treated with Alu RNA, our investigation into the mechanism of their
protective effect revealed that NRTIs possess an intrinsic NLRP3 inflammasomeinhibitory effect that did not require their phosphorylation. Since NRTI phosphorylation
is required in order for their function as reverse transcriptase inhibitors, our findings
indicate that the inflammasome-inhibitory effect we observed occurs independently of
reverse transcriptase inhibition. Using one NRTI (d4T; stavudine) to explore the
mechanism of this intrinsic anti-inflammatory effect, we showed that d4T selectively
antagonized P2X7 function and was remarkably protective in other P2X7-dependent cell
culture and animal models that are not known to signal via reverse transcriptase.
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Chapter 2 Nucleoside reverse transcriptase inhibitors block Alu-induced RPE
degeneration and NLRP3 inflammasome activation
2.1

Introduction

Degeneration of the RPE is hallmark of dry AMD, and is thought to be an inciting
event in the disease pathogenesis. The NLRP3 inflammasome is a common integrator of
multiple AMD-related stressors (see discussion 2.4.1), and an essential mediator of Aluinduced RPE toxicity.
Like Alu RNA, HIV is another pathogen that activates the NLRP3 inflammasome
(see discussion 3.4.5). We noticed a similarity between Alu RNAs and HIV: their life
cycles both require reverse transcriptase (Fig. 2.1). Although it is clear that inhibition of
the viral life cycle with nucleoside reverse transcriptase inhibitors (NRTIs) is part of a
functionally curative treatment regimen in the case of HIV, it is not known whether
NRTIs inhibit Alu-induced NLRP3 activation or RPE degeneration.
As such, the present studies were designed to investigate whether NRTIs prevent
RPE degeneration induced by Alu RNA. We will test the hypothesis that NRTIs inhibit
the NLRP3 inflammasome, which in turn dampens the signaling pathways that drive RPE
degeneration.
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Figure 2.1 Reverse transcriptase-dependent replication of Alu RNA and HIV RNA.
Alu and HIV RNAs are genomic parasites. The life cycle of each RNA involves
transcription from the host genome into an RNA intermediate, followed by reverse
transcription and re-integration as a copy elsewhere in the genome.

2.2
2.2.1

Materials and Methods
Cell culture

Primary human RPE cells were isolated and purified from fetal retina (gift from
D. Hinton, University of Southern California). Primary mouse RPE cells were isolated
from C57/Bl6J mice. Cells were used for experiments between passages of 4 and 7, with
routine split of cells at 1:3 with each passage.
RPE cells were cultured in high-glucose DMEM with 10% (human) or 20%
(mouse) fetal bovine serum (FBS) supplemented with 2 mM L-Glutamine and 100 U/mL
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Penicillin/Streptomycin (P/S). Transfection of Alu RNA was performed using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions. For
transfection in 6 well dishes, RPE cells were transfected with 1.5 mL of plating media
(DMEM 10 or 20%, as above, except without P/S) and 500 µL of transfection mix in
Opti-MEM (Invitrogen). For a 6 well dish, the transfection mix consisted of 10 µg
(approximately 100 pmol) of in vitro transcribed Alu RNA (see below) and 5 µL
Lipofectamine 2000. Cells were transfected at approximately 70 % confluency, and
media was replaced with 10% DMEM (+ P/S), with inhibitors, eight hours after
transfection. Protein for western blot was collected at 24-30 hours after transfection (see
below).
NRTIs (d4T (stavudine), 3TC (lamivudine), AZT (zidovudine), ABC (abacavir))
were obtained from Sigma-Aldrich. NRTI powders were reconstituted in UltraPure water
(Invitrogen) and added to cell culture media at a final concentration of 25-100 µM (for 2
mL final volume) 20 minutes before transfection mix was added to cells.
In vitro transcribed RNA was synthesized using the AmpliScribe-T7 High Yield
Transcription Kit (Epibio) from a DraI-linearized plasmid containing an AluY sequence
with upstream T7 promoter sequence (see Appendix for plasmid information; plasmid
gift of James A. Goodrich, University of Colorado).
2.2.2

Western blot

Protein samples were run on 4-20% or 4-12% tris-glycine SDS-PAGE gels,
transferred to PVDF membrane (0.2 or 0.45 µm), and blotted with antibodies against
Caspase-1 (1:500, Invitrogen); pIRAK4 (1:500, Cell Signaling); Vinculin (1:1,000,
Sigma-Aldrich). Cells were homogenized in RIPA buffer (Sigma) with protease and
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phosphatase inhibitors (Roche) or lysed directly in 1x Laemmli buffer (4x recipe: 8%
SDS; 20% 2Mercapto-ethanol; 40% glycerol; 0.04% bromophenol blue; 0.25 M Tris-HCl
pH 6.8). For RIPA extraction, protein concentrations were determined using a Bradford
assay kit (Bio-Rad) with bovine serum albumin as a standard. Primary antibody
incubation was performed overnight at 4 °C. Protein loading was assessed by
immunoblotting using an anti-vinculin antibody. Secondary antibodies (Santa Cruz,
1:5000; or LICOR, 680/800 nm IRdyes, 1:20000) were used for 1 hour at room
temperature. The signal was visualized using a luminol detection kit (Santa Cruz) and
captured on UltraCruz ultraradiography film (Santa Cruz) or using the LICOR Odyssey
Imager.
2.2.3

Mice

Ocular animal experiments were in accordance with the Association for Research
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and
Visual Research. All experiments were performed on wild-type male C57BL6/J mice age
6-8 weeks, purchased from The Jackson Laboratory. Mice were habituated for at least 72
hours in the Division of Laboratory Animal Resources upon arrival to the University of
Kentucky and housed in plastic cages (bedding and enrichment) with cage mates and ad
libitum access to food and water and maintained on a 14:10 hour light:dark light cycle.
For all procedures, anesthesia was achieved by intraperitoneal injection of 100 mg/kg
ketamine hydrochloride (Ft. Dodge Animal Health) and 10 mg/kg xylazine (Phoenix
Scientific), and pupils were dilated with topical 1% tropicamide (Alcon Laboratories).
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2.2.4

Alu-induced model of RPE degeneration and drug administration in
mice
Subretinal injections (SRI) (1 µL) in mice were performed using an Ito
microsyringe (Ito Corporation). In vivo transfection of plasmids coding for an Alu
sequence (pAlu) or empty control vector (pNull) was achieved using 10% Neuroporter
(Genlantis) as described previously

31

. For oral administration, d4T was mixed with

carboxymethylcellulose (CMC) sodium salt (Sigma) (final concentration of CMC was
0.5%) delivered once daily by oral gavage at 150 mg/kg, or twice daily (every 12 hours)
by oral gavage at 50 mg/kg (total 100 mg/kg/day). CMC alone was used as vehicle
control. For intraperitoneal injection of AZT, AZT was dissolved in UPS-grade 1x PBS
(Gibco) was administered twice daily (50 mg/kg/administration) for (vs. control PBS).
For both oral gavage and intraperitoneal administration, NRTIs (or control) were
delivered daily, starting in the evening one day before morning-time SRI, and lasting
until six days after SRI, at which time the experimental timeline concluded. Technical
assistance with animal procedures was provided by Younghee Kim (Ambati Lab).
2.2.5

Fundus photography

Fundus imaging of dilated mouse eyes (see section 2.2.3 Mice) was performed on
a TRC-50 IX camera (Topcon) linked to a digital imaging system (Sony).
2.2.6

RPE flat mount, ZO-1 staining and confocal imaging

Briefly, mouse RPE/choroid flat mounts were fixed with 4% paraformaldehyde or
100% methanol, stained with antibodies against zonula occludens-1 (ZO-1) and
visualized with Alexa594 (Invitrogen). All images were obtained using the Leica SP-5
microscope. Detailed protocol is as follows:
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1. After fundus photograph, euthanize mouse and remove entire eyeball with forceps
(grabbing the optic nerve).
2. Slit the cornea and remove cornea, lens, and neural retina tissues, leaving behind the
retinal pigment epithelium/choroid complex (RPE/C).
3. Fix the RPE/C and Sclera in 2% paraformaldehyde/1x PBS for 30 min at 4° C, with
gentle shaking.
4. Wash in 1x PBS for 5 min (× 2) at 4°C.
5. Wash in 10 mM TBS for 5 min (× 2) at 4°C.
6. Permeabilize in 10 mM TBS-T (containing 0.2% Triton X-100) for 20 min at 4°C,
with gentle shaking.
7. Incubate in Blocking Buffer (3% BSA + 2% NGS/TBS-T) for 2-4 h at 4°C.
8. Incubate in primary antibody (rabbit ZO-1; Invitrogen #61-7300)(1:50 in Blocking
Buffer) overnight (~>16 h) at 4°C.
9. Wash in 10 mM TBS-T for 5 min (× 3) at 4°C. Protect samples from light for all
following steps.
10. Incubate in secondary antibody (AF594 goat anti-rabbit IgG, 1:500 in Blocking
Buffer) for 2 h at 4°C.
11. Wash in 10 mM TBS-T for 5 min (× 3) → 10 mM TBS for 10 min (× 1) at 4°C.
12. Cut radially and wet-mount the RPE flats using Vectasheld (≈ 55 ul/flat).
13. Photography using the AOBS SP5 confocal microscope in BBSRB confocal suite.
Settings: * HyD488/594 (Offset: 0): Laser power (A594): 30% - Gain: 30% - Pinhole:
100%.
2.2.7

Northern blot

Total RNA from biotin-UTP Alu RNA-transfected cells was extracted using
Trizol reagent (Invitrogen) according to the manufacturer’s instructions. RNA samples
were run on 10% TBE-urea gels (Biorad) at 150 V in 1x Tris-Borate-EDTA (TBE)
running buffer. Samples were transferred from the gel to a HyBond N+ nylon membrane
(GE) using a wet transfer method (0.5x TBE transfer buffer; 1 hr at 75 V; on ice;
transfers can also be performed overnight in cold room (4 °C) at 30 V). After briefly
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drying at room temperature (about five minutes), the membrane was UV cross-linked
(240 mJ/cm2). Membrane was blocked in pre-hybridization buffer (Recipe: 10 mL
deionized formamide, 5 mL NaH2P04 pH 7.2, 1 mL NaCl 5M, 160 uL EDTA 250 mM, 3
mL h20, add 1.4 g SDS; denatured herring sperm DNA, 300 µL (100 °C, 5 min).
Membrane blocked at 42 °C for at least 30 minutes before addition of probe. Membrane
was blotted for u6 RNA loading control using a biotinylated oligonucleotide probe
synthesized by IDT (5’ CACGAATTTGCGTGTCATCCTT-Biotin 3’), with
hybridization at 42 °C overnight in a glass tube rotating in a rotisserie hybridization oven.
After overnight hybridization, membranes were washed in 2xSSC, 0.1% SDS, twice, for
15 minutes each wash, at 42 °C, and then developed with the Thermo Pierce
chemilluminescent nucleic acid detection kit according to the manufacturer’s instructions,
and captured on UltraCruz ultraradiography film (Santa Cruz).

2.2.8 Densitometry
Densitometry for western and northern blots was performed using ImageJ
software and according to the instructions included therein 32. For each experiment, all
blots of biological replicates (“n”) were analyzed independently and normalized to
housekeeping gene (vinculin). Mean values of experiments are presented in
representative images.

2.2.9 Fisher’s exact test for fundus photograph analysis
Fisher’s exact test (two-tailed) was performed for fundus photographs using
GraphPad software. Fundus photographs were de-identified and graded as “yes” or “no”
in terms of induction or prevention of RPE degeneration, respectively. Typical induction
of RPE degeneration by Alu was about 25% of the visible area of the fundus photograph.
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2.3
2.3.1

Rationale and Results
NRTIs inhibit Alu-induced NLRP3 inflammasome activation

Since Alu and HIV both rely on reverse transcriptase for their life cycle, we
hypothesized that NRTIs block Alu RNA-induced cytotoxicity. Alu RNA mediates RPE
cell death via activation of Caspase 1 and the NLRP3 inflammasome 28,30. The NRTI
stavudine (d4T; 2’3’ dideoxythymidine; Zerit, Bristol-Myers Squibb), which is FDAapproved for the treatment of HIV infection, prevented Caspase 1 cleavage to its active
(p20) form 33,34 in primary human (Fig. 2.2 a) and wild-type mouse RPE cells (Fig. 2.3 a).
Importantly, d4T did not reduce Alu RNA levels (Fig. 2.3 b), as determined by northern
blot of human RPE cells transfected with biotin-UTP body-labeled Alu RNA with or
without d4T treatment (for detailed methods see Section 2.2.7). Several time points were
analyzed (1, 4 and 24 hours), which span the course of typical in vitro experiments to
analyze Alu-induced molecular effects (e.g. Caspase-1 cleavage at 24 hrs; peak ATP
release from cells at 4-6 hours). This result indicates that d4T prevents Alu-induced
Caspase-1 activation downstream of Alu RNA accumulation (i.e. it does not simply
prevent Caspase-1 activation by modulating Alu RNA levels). As such, we next sought to
determine whether d4T blocked other molecular hallmarks of the model established in
previous work and depicted in Figure 1.3.
Indeed, d4T also blocked phosphorylation of IRAK4, a kinase downstream of the
MyD88 adaptor that mediates Alu RNA-induced RPE cell death 28, in primary human and
wild-type mouse RPE cells (Fig. 2.2 a and Fig. 2.3 a). Other NRTIs, including the antiHIV drugs azidothymidine (AZT; 3'-azido-2',3'-dideoxythymidine; Retrovir, ViiV
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Healthcare), lamivudine (3TC; 2’3’ dideoxycytidine; Zeffix, GlaxoSmithKline) and
abacavir (ABC; a di-deoxyguanosine analog; Ziagen, ViiV Healthcare), also blocked
Caspase-1 cleavage induced by Alu RNA (Fig. Fig. 2.2 b).

2.3.2

NRTIs inhibit Alu-induced RPE degeneration in mice

NRTIs are typically administered orally to HIV patients, in pairs, at a total NRTI
dose of up to 15 mg/kg/day (equivalent dose in mice: 185 mg/kg/day). Twice daily
administration of oral d4T (every day throughout the course of the experiment; see
Section 2.2.4) at a clinically relevant dose (100 mg/kg/day) in wild type mice prevented
Alu-induced RPE degeneration 28,31 (Fig. 2.2 c; p = 0.0003; n = 12). 9 of 12 eyes from
d4T-treated mice were protected from RPE degeneration, whereas all 12 eyes from
vehicle-treated mice exhibited RPE degeneration. Also, a single administration of oral
d4T at 150 mg/kg/day (again, daily throughout the course of the experiment) prevented
Alu-induced RPE degeneration (p = 0.015, n = 6 per group), with 5 out of 6 eyes from
d4T-treated mice protected from Alu-induced RPE degeneration, and all 6 eyes from
vehicle-treated mice exhibiting degeneration. Finally, Alu-induced RPE degeneration in
wild type mice was also blocked by twice daily intraperitoneal administration of 50
mg/kg AZT (daily throughout the course of the experiment).
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Figure 2.2 NRTIs block Alu-induced RPE degeneration and Caspase-1 activation
(A) Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in
primary human RPE cells transfected with Alu RNA + d4T (100 µM).
(B) Western blot of Caspase-1 activation in human RPE cells transfected with Alu RNA
+ NRTIs (3TC, AZT, ABC) (100 µM).
(C-D) Fundus photographs (top row) and flat mounts stained for zonula occludens-1 (ZO1; red) (bottom row) show that (C) twice daily oral administration of d4T (50 mg/kg;
total 100 mg/kg/day) and (D) twice daily intraperitoneal administration of AZT (50
mg/kg; total 100 mg/kg/day) prevented RPE degeneration induced by a plasmid
expressing Alu RNA. In fundus photographs degeneration outlined by blue arrowheads.
Scale bars, 50 µm. See also Figure 2.3. Images representative of n = 3-4 (a,b), n = 8-12
(c,d). Fisher’s exact test p-value of (c) pAlu + vehicle vs. pAlu + d4T: 0.0003; (d) pAluA
+ vehicle vs. pAlu + AZT: 0.0004.

	
  

21	
  

	
  

Figure 2.3 d4T blocks Caspase-1 activation without reducing Alu RNA levels.
(A) Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in
primary mouse RPE cells transfected with Alu RNA + d4T (100 µM). Image
representative of n = 4.
(B) Northern blot of biotin-UTP-labeled Alu RNA-transfected primary human RPE cells.
D4T (100 µM) did not reduce Alu RNA levels (normalized to u6 RNA). Alu RNAtransfected cells in culture assayed at 24 hours for western blotting (Fig. 2.2 a-b, Fig. 2.3
a).
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2.4
2.4.1

Discussion
Drug repurposing of NRTIs for dry AMD

There are no effective therapies for dry AMD; therefore, our finding that NRTIs
are effective in a mouse model of disease are of great importance in terms of their
potential as therapeutics. The use of NRTIs to fill this niche is particularly appealing
given the advantages of repurposing FDA-approved drugs. Drug repurposing surmounts
major obstacles of traditional drug development of novel compounds; importantly, the
costs of development are greatly reduced; the time from clinical investigation to FDAapproval is minimized; safety risks are limited because the toxicity profile and
pharmacokinetics of these compounds has already been extensively demonstrated 35,36.
Drug repurposing of NRTIs should also be a boon for patients as these drugs are off
patent and predictably inexpensive.
The translatable potential of NRTIs would be bolstered by future investigations
showing their protective effect in other models of dry AMD. We predict that NRTIs will
be similarly effective in other models of dry AMD, which are also driven by the NLRP3
inflammasome. Based on the concordance of these models with human data, it is
increasingly apparent that the NLRP3 inflammasome is a convergent integrator of
multiple AMD-associated molecular stressors (e.g. Alu RNA 28; lysosomal destabilization
37

; oxidative stress 38; A2E 39; beta-amyloid and complement 40,41.
If nucleoside analogs are to be explored as potential therapeutic agents in humans,

it will also be important to consider that patients with dry AMD are at greatly increased
risk of also developing CNV 1. Future work could determine whether NRTIs affect CNV
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in mice. Data in press from our laboratory indicate that inflammasome inhibition does not
affect CNV, although other studies suggest that the inflammasome might modulate CNV
42,43

. Regardless of whether the NLRP3 inflammasome drives CNV, it will be important

to directly test any putative therapeutic agent for the treatment of dry AMD in terms of its
effect on CNV.
2.4.2

Translational considerations: Dosing and route of administration

NRTIs are typically administered as oral pills in adult humans. This method of
delivery is convenient and well understood from a pharmacokinetic and adverse effect
standpoint. We recapitulated oral administration in our mouse model of dry AMD,
showing that oral d4T blocked Alu-induced RPE degeneration. The dose that optimally
blocked RPE cell death was twice daily administration of 50 mg/kg d4T (total 100
mg/kg/day), which is the biological equivalent of about 8 mg/kg/day in humans, based on
body weight and surface area conversion 44. The dose used in our experiment is therefore
about four times as high as the amount of d4T administered in humans (~ 2 mg/kg/day).
However, a typical adult human regimen for HIV therapy includes a pair of NRTIs (e.g.
40 mg d4T and 400 mg didanosine; 150 mg lamivudine (3TC) and 300 mg zidovudine
(AZT)), twice a day 45-47. Therefore, the total dose of NRTI delivered in our experiments
was considerably lower compared to human equivalent doses. For example, the NRTI
load of monotherapy AZT for a 60 kg human would be 10 mg/kg/day, or the equivalent
of 123 mg/kg/day in mice, whereas we prevented RPE degeneration at a dosing regimen
of 100 mg/kg/day of AZT in our Alu-induced model. Importantly, the therapeutic doses
required in humans would be expected to be dramatically even lower considering the
acute, powerful nature of Alu stimulus in mice compared to a more insidious
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development of RPE disease (progressing on the time scale of years to decades) in the
human condition.
This rationale suggests that many of the side effects attributed to NRTI use (e.g.
bone marrow suppression; peripheral neuropathy; lipodystrophy)48 could be avoided, or
at least greatly reduced, in AMD therapy. For example, in AZT monotherapy trials,
unlike high doses of AZT (1500 mg/day) low doses (500 mg/day, which is three times
higher than the equivalent surface area-body weight conversion in mice) did not produce
hallmark adverse effects of neutropenia and anemia compared to placebo after a mean
follow-up of 55 weeks. In fact, nausea was the only adverse effect with significant
increase in patients taking low-dose AZT compared to placebo 49. The side effects
experienced with d4T use (e.g. peripheral neuropathy) are also well characterized in
terms of dose-dependence 50, which would facilitate dose optimization to avoid adverse
events in AMD patients taking NRTIs.
Another approach to avoiding adverse effects associated with high doses of a
single NRTI would be to combine NRTIs into a single formulation; since multiple NRTIs
appear to have similar protective effects in vitro and in vivo for the Alu-induced model of
GA, yet different toxicity profiles, one could imagine that a formula combining low doses
of multiple NRTIs might be as effective at blocking RPE degeneration as a large dose of
a single NRTI (this could be explored in future experiments).
Yet another drug delivery option would be intraocular administration. An
important issue to be further elucidated is whether the effect of NRTIs is a direct effect in
the eye. In preliminary experiments we noted that ocular delivery (intravitreous injection)
of d4T prevented RPE degeneration in the Alu-induced model. Consistent with the idea
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that d4T and NRTIs can act locally on the RPE, the data presented herein (Fig. 2.2)
indicate that d4T can produce a direct effect on RPE cells in culture. If NRTIs act locally
in the eye, then systemic administration of NRTIs, which have a short half-life (20-30
minutes in mice; 60-120 minutes in humans) 51,52, is probably an inefficient mode of
delivery to the site of RPE cell death 53. Future work could determine the efficacy of
topical (e.g. eyedrops) 54 or intravitreous delivery of NRTIs in the Alu and other models
of dry AMD.

2.4.3

NRTI-induced cell dysfunction

Although NRTI use has been associated with various cell toxicities, including
reduced viability, mitochondrial function and proliferation, and increased lactate
production 55-57, RPE cells exposed to NRTIs up to 100 µM do not exhibit a reduction in
cell viability or cell death (at one week in mice; 48-72 hrs in cell culture) (unpublished
observations monitored by ZO-1 flatmount/fundus imaging (in vivo) and MTS assay (in
vitro)). NRTI-induced dysfunction of non-RPE cells is attributed primarily to mtDNA
defects; perhaps RPE cells are resistant to NRTI-induced dysfunction because of their
great metabolic capacity in vivo (highest metabolic rate per weight of tissue 10, and as
such they have a large buffer capacity. Furthermore, it is known that the kinases
responsible for phosphorylating certain pyrimidine NRTIs (e.g. AZT) are elevated during
mitosis 58; post-mitotic (in vivo) or slowly dividing (in vitro) RPE cells may be resistant
to NRTI-induced toxicity due to low expression of such kinases, an issue that could be
addressed in future work.
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2.4.4

Risk of AMD in humans taking NRTIs

A potential corollary to the presented findings would be that HIV patients might
be at reduced risk of developing AMD because of their chronic exposure to NRTIs. Until
now, it has not been possible to address this question for several reasons. In order to have
sufficient power to detect a significant clinical difference, a study population of about
2,000 controls and HIV patients would be required: The point prevalence of pure GA is
about 2% in those over 70 and 3% in those over 75 59,60. To have 80% power to detect a
change in the rate from 2% to 1% in 70 year olds, one would need 2276 participants in
each group and to detect a change in the rate from 3% to 1.5% in those over 75 one
would need 1506 participants in each group (correspondence Chelsea E. Myers, M. Stat,
University of Wisconsin-Madison). However, the number of reported HIV positive
patients aged 65 and older has been low until just recently (6,580 in 2001 vs. 36,462 in
2010) 61,62. As such, the logistics of such an analysis are becoming increasingly feasible.
However, there are several important challenges to an analysis of AMD
phenotype in HIV patients. For one, such a study will need to take into account the
number of years and dosing of multiple NRTIs. Also, one would need to consider that
HIV patients take a number of other anti-viral drugs (e.g. protease inhibitors and nonnucleoside reverse transcriptase inhibitors), including ritonavir, which is associated with
RPE abnormalities 63.
In this respect, patients with chronic hepatitis B virus (HBV; affecting 350 million
people worldwide) might be a better study population for assessing the effect of NRTIs
on AMD phenotype. The NRTI lamivudine (3TC) is used long-term in some HBV
patients (e.g. median treatment duration 90 months; 64) including the elderly (60 years
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and older; 65). Moreover, in contrast to HIV 66, unmanaged HBV is not known to cause
retinal abnormalities.
Even if HIV/HBV patients are at reduced risk of developing AMD, it will not be
possible to parse out the effects of virus from NRTI use. Although a population of longterm NRTI users does not currently exist, it is possible that one will exist in the future.
The NRTI-containing prophylactic Truvada® was approved in 2012 by the FDA for HIV
prevention (or “pre-exposure prophylaxis”). If the at-risk-for-HIV patient population
were to take this NRTI compound for decades, and remain HIV-free, then this would be
an ideal population to parse the effects of virus from NRTI on AMD. However, such an
analysis of NRTI use in HIV-free individuals would likely require decades of NRTI
exposure and is predicated on the efficacy of prophylaxis, and survival of the population
until a reasonable prevalence of AMD occurs in order to perform a sufficiently powered
statistical analysis (see discussion earlier in section 2.4.4).
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Chapter 3: NRTIs block NLRP3 inflammasome activation independent of reverse
transcriptase inhibition
3
3.1
3.1.1

Introduction
Life cycle of Alu RNA

Human cells contain a variety of active, endogenous reverse transcriptases (RTs),
including L1 67 and telomerase 68. These enzymes are broadly expressed and functional in
multiple cell types, in both health and disease 69-73. However, RPE cells do not express
telomerase 74, and it is not known whether RPE have other sources of endogenous RT
activity. Nevertheless, given that Alu RNA is a known substrate for RT, and that NRTIs
block Alu-induced toxicity, it is worth discussing the plausibility that Alu RNA activates
the NLRP3 inflammasome via RT, and that the protective effect of NRTIs observed in
Chapter 2 is achieved via their classic RT inhibitor function.
Reverse transcription of Alu RNA is known to occur in somatic cells in a process
that requires the host-encoded endogenous RT known as L1 67. In this process, known as
retrotransposition, RT of Alu RNA by L1 is coupled to insertion of Alu RNA into the
genome via a target-primed-reverse transcriptase mechanism that involves priming of the
first strand cDNA by the host chromosome 26,75,76. At present it is clear that insertion of
an Alu copy into a new chromosomal locus can produce a plethora of genomic
disruptions, for example: insertional mutagenesis, transduction, and ectopic
recombination 77. RT inhibition would prevent successful integration events, and
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therefore much of this genomic instability. As Alu RNAs are increased in the human RPE
of dry AMD patients, it would be interesting to determine if these patients also have
increased levels of genomic Alu DNA levels, which could be answered using the “RC–
seq” technique, which involves hybridization of genomic Alu sequences to a microarray
chip, followed by next-generation sequencing and mapping of novel Alu insertions
compared to the known reference human genome(s) 69. As RPE cells are typically postmitotic, they are optimal system for studying somatic retrotransposition, as Alu insertions
would be fossilized throughout life.

3.1.2

Arguments against RT-mediated Alu RNA-induced RPE degeneration

The original rationale for this dissertation was based on the similarity in life cycle
of Alu and HIV RNAs (Fig. 2.1). However, upon a detailed examination of the literature,
we questioned the likelihood RT inhibition was responsible for the observed antiinflammatory effects of NRTIs in the Alu-induced model of AMD. Therefore, in Chapter
3, we directly test whether the ability of two NRTIs to block RPE degeneration and
inflammasome activation is mediated by reverse transcriptase inhibition. The following
considerations led us to question our original rationale.
In pilot cell culture experiments, we noted that NRTIs blocked inflammasome
activation by other stimuli, such as lipopolysaccharide/ATP, which are not known to
signal via reverse transcriptase. Furthermore, partial inhibition of this inflammasome
activation and RPE cell death by NRTIs was seen at 25 µM, with optimal rescue,
typically full blockade of Caspase-1 processing to its p35 intermediate active form, or
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IRAK4 phosphorylation, was seen at doses of 50-100 µM (Fig. 3.1). However, this NRTI

Figure 3.1. d4T blocks LPS/ATP-induced Caspase-1 activation and IRAK4
phosphorylation in primary human RPE cells. Activation of Caspase-1 seen by
processing to its intermediate active 35 kDa band. Image representative of n = 2-3
experiments.
dose is much higher than the IC50 of known endogenous reverse transcriptases, and
therefore not consistent with the idea that reverse transcriptase mediates Alu-induced
toxicity. For example, the IC50 of various NRTIs we tested (Fig. 2.2 a-b) for L1mediated retrotransposition is in the low micromolar range 78,79 (0.22 to ~ 5 µM). In
addition, the in vitro transcribed Alu sequence used in our studies lacks a polyA tail; it is
known that Alu sequences lacking a polyA are not mobilized by L1 80.
Furthermore, RPE cells do not exhibit telomerase activity 74, but even if they
expressed a very low amount, the IC50 of telomerase by NRTIs is also not compatible
with the hypothesis that telomerase mediates the observed effect that NRTIs block
inflammasome activation in vitro. For example, the IC50 of the triphosphate forms of
AZT and d4T are 44 and 24 µM, respectively 81. Since only a small fraction (0.5-2%) of
intracellular AZT and d4T is metabolized by the cell to their triphosphate forms 82, NRTI
concentrations on the order of hundreds of micromolar or low millimolar would be
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required to achieve these levels of triphosphate in cells. Indeed, telomere shortening
induced by AZT is only observed after weeks of culture at 100-800 µM 83,84.
Alternatively, it is conceivable that NRTIs could function as nucleosidetriphosphates through inhibition of non-RT enzymes, such as other host DNA
polymerases. Inhibition of DNA polymerase-gamma by NRTIs (IC50s are much lower
for -gamma compared to other DNA polymerases) leads to a reduction in mtDNA levels,
a mechanism that is thought to drive mitochondrial effects of anti-HIV therapy 55,85. Since
the release of mtDNA from the mitochondrion to cytoplasm is a known trigger for
NLRP3 activation 86, at first glance mtDNA depletion seems like a plausible mechanism
by which NRTIs could inhibit inflammasome activation. However, as will be addressed
in this chapter, inflammasome inhibition in our model is achieved before significant
reductions in mtDNA are observed. Finally, different NRTIs have dramatically different
ranges of IC50 for DNA polymerase gamma 85 despite showing a similar effective dose
in blocking Alu-induced inflammasome activation, suggesting that this pathway is not a
crucial mediator of the protective effect of NRTIs. Therefore, to test directly whether
NRTIs are anti-inflammatory via reverse transcriptase inhibition, we utilized two systems
in which the NRTIs d4T and AZT were not capable of becoming phosphorylated: we
synthesized a methoxy-substituted variant of d4T, and also tested AZT in a cell line that
lacks thymidine kinase (the enzyme required for the first phosphorylation step of AZT).
In these systems, despite this incapacity for phosphorylation, these NRTIs still blocked
NLRP3 inflammasome activation.
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3.2 Materials and methods
3.2.1 Cell culture
Please refer to section 2.2.1. For pilot LPS/ATP experiments in primary human
RPE (Fig. 3.1), confluent RPE cells were primed for four hours with 1000 ng/mL LPS in
10% DMEM + P/S media. At t = 4 hrs, media was changed and 5 mM ATP (pH adjusted
to 7.4) was added to fresh media and added to cells for 5 minutes. Lysates were collected
directly in 1x laemmli buffer (section 2.2.1), boiled for 5 minutes, and loaded on gel for
western blot analysis.
The following protocol was used for precipitation of protein from cell culture
media for western blot, and adapted from 87:

1. Add 1 volume of Trichloroacetic acid (TCA) (100% w/v) to 4 volumes of protein
sample.
2. Shake and incubate 10 min at 4°C.
3. Spin tube in microcentrifuge at 14,000 rpm for 5 min.
4. Remove supernatant, leaving protein pellet intact. Pellet should be formed from
whitish, fluffy ppt.
5. Wash pellet with 200 ul ice-cold acetone.
6. Spin tube in microcentrifuge at 14,000 rpm for 5 min.
7. Repeat steps 4-6 for a total of 2 acetone washes.
8. Dry pellet by placing tube in 95°C heat block for 5-10 min to drive off acetone, and
resuspend in 1-2x laemmli buffer, boil for 5 minutes, and load on gel for western blot
analysis.

	
  

33	
  

	
  
3.2.2

Design and synthesis of methoxy-d4T

Synthesis was commissioned to Tocris (Bristol, United Kingdom). A schematic of
the synthesis is depicted in Fig. 3.2. Figs. 3.2-3.3 (quality control assays) performed by
Tocris. The first batch of compound was poorly water-soluble compared to unmodified
d4T. Subsequently, we dissolved the compound in 100% DMSO to create a concentrated
stock solution.
3.2.3

Lentivirus replication assay

100 µM d4T or me-d4T was added to HeLa cells two hours before addition of a
lentivirus-GFP particle (generated at the University of Kentucky; Dr. M. Mendenhall) at
a multiplicity of infection of 10. At 24 hours an additional 100 µM d4T or me-d4T was
added to cells, and at 48 hours cells were briefly fixed in 4% PFA (1-2 minutes) and
washed with 1x phosphate buffered saline before imaging. Technical assistance with
imaging provided by Bradley Gelfand (University of Kentucky). For cell counting of
GFP-positive cells, four fields were chosen at random for each condition, images were
processed at the same threshold, and GFP-positive cells were counted using ImageJ.
3.2.4

Quantitative polymerase chain reaction

Total DNA was extracted from cells and amplified by real-time quantitative PCR
(Applied Biosystems 7900 HT Fast Real-Time PCR system) with Power SYBR green
Master Mix. Oligonucleotide primers specific for mouse mtDNA COX1 (F 5’ TTC GGA
GCC TGA GCG GGA AT 3’; R 5’ ATG CCT GCG GCT AGC ACT GG 3’) were used
and normalized to a genomic DNA exon-intron junction of the gene Dicer1 (F 5’ GTG
AGG CGG GCT CCC TGC TG 3’; R 5’ CTT CGA ACG CGG AAC GGG ACC 3’). The
qPCR cycling conditions were 50 °C for 2 min, 95 °C for 10 min followed by 40 cycles
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of a two-step amplification program (95 °C for 15 s and 58 °C for 1 min). At the end of
the amplification, melting curve analysis was applied using the dissociation protocol from
the Sequence Detection system to exclude contamination with unspecific PCR products.
Relative expressions of target genes were determined by the 2 - ΔΔCt method.
3.2.5

Western blot
Please refer to section 2.2.2.

3.2.6

Mice
Please refer to section 2.2.3.

3.2.7

Alu-induced model of RPE degeneration and mouse drug
administration
Please refer to section 2.2.4.

3.2.8

Fundus photography
Please refer to section 2.2.5.

3.2.9

RPE flat mount, ZO-1 staining and confocal imaging
Please refer to section 2.2.6.

3.2.10 Liquid chromatography/Mass spectrometry
HPLC was run using a 2 Varian ProStar model 210 HPLC solvent delivery
module and a Phenomenex Kinetix C-18 column (100 mm x 2.1 mm x 2.6 µM). Solvent
compositions were (A): 3 mM Ammonium formate and 10 mM N,N-dimethylhexylamine
in H20; (B): 1:1 acetonitrile:H2O with 3 mM Ammonium formate and 10 mM N,Ndimethylhexylamine. HPLC mobile phase and flow rate are listed in Table 3.1.
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Time (min)

A%

B%

Flow (mL/min)

0

95

5

0.2

3

95

5

0.2

25

40

60

0.2

26

0

100

0.2

29

0

100

0.2

30

95

5

0.2

40

95

5

0.2

Table 3.1. LC/MS parameters. HPLC mobile phase and flow rate.

Mass Spectrometry was performed on a Varian 1200 L quadrupole MS/MS. Analytes
were analyzed with electrospray ionization on negative mode. Cell extracts from Raji TK/+

cells were prepared by adding 40% acetonitrile/20% methanol/20% water to cell

pellets, incubation at -20 °C for 15 minutes followed by centrifugation at 4 °C for 5
minutes at 20,000 x g. Two sequential extractions were performed per cell pellet, pooled,
and stored at – 80 °C until analysis. Technical assistance provided by John May
(University of Kentucky).
3.2.11 Fisher’s exact test for fundus photograph analysis
Please refer to section 2.2.9.
3.3 Results
3.3.1 Methoxy-d4T does not inhibit polymerases
In order to test whether reverse transcriptase inhibition was required for
inflammasome blockade by d4T, we synthesized a novel 5’ O-methyl-modified version
of d4T (5’-OCH3-d4T; me-d4T) (Fig. 3.2 a; Figs. 3.3-3.4). Only the triphosphate forms
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of nucleoside analogs inhibit reverse transcriptase; the methyl modification at the 5’
position prevents phosphorylation and thus formation of nucleoside triphosphate, as has
been demonstrated in previous work using short-interfering RNAs 88. As predicted, med4T did not inhibit reverse transcriptase using a lentivirus replication assay. A detailed
methodology of this assay can be found in Section 3.2.3; the principle of this assay is,
briefly, that the particles used in this assay contain RNA lentiviruses that require reverse
transcription for conversion to their DNA form, and only then are able to express a green
fluorescent protein encoded by the virus. In contrast to unmodified d4T, me-d4T did not
block lentivirus reverse transcription in HeLa cells as monitored by a GFP reporter (Fig.
3.2 b-c). Moreover, the triphosphate metabolite of di-deoxy nucleoside analogs causes
depletion of mitochondrial DNA: NRTI-triphosphates are incorporated into a growing
strand of mitochondrial DNA by DNA polymerase gamma, and the lack of a 3’ hydroxyl
group halts strand elongation and leads to abortion of the nascent DNA strand synthesis
85,89,90

. Consistent with the idea that me-d4T is not phosphorylated, we found that d4T,

but not me-d4T reduced mtDNA levels as measured by quantitative PCR for the Cox1
mtDNA gene and normalized to genomic DNA by quantitative PCR for an exon-intron
junction (at a locus within Dicer1) in primary mouse RPE cells (Fig. 3.2 d) after 48 hours
of drug exposure.
3.3.2

Methoxy-d4T blocks inflammasome activation and prevents RPE
degeneration

Remarkably, despite its inability to inhibit polymerases, me-d4T still blocked
Caspase-1 activation in primary human RPE cells (Fig. 3.2 e). We confirmed that me-d4T
also prevented Alu-induced RPE degeneration in wild-type mice (Fig. 3.2 f; p = 0.03; n =
4 eyes/group). Four of four eyes from me-d4T-treated mice were protected against Alu-
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induced RPE degeneration, whereas all four eyes from vehicle-treated mice exhibited
degeneration. These data indicate that d4T can block Caspase-1 activation and RPE
degeneration independent of reverse transcriptase inhibition.
3.3.3

NRTIs block LPS/ATP-induced inflammasome activation

We also tested whether NRTIs blocked inflammasome activation by
lipopolysaccharide (LPS; a component of the cell wall of gram negative bacteria) and
ATP, a stimulus not known to signal via reverse transcriptase 29,91,92. After stimulating
primary mouse bone marrow-derived macrophages with 1000 ng/mL LPS for four hours,
the addition of ATP (5 mM in serum-free media) induced secretion of the active p20
form of Caspase-1 into the cell culture media. Cell culture media was concentrated with
trichloroacetic acid and immunoblotted for Caspase-1. Data were normalized to western
blot of pro-Caspase-1 levels in cell lysates, collected directly in 1x laemmli buffer. We
found that d4T inhibited LPS/ATP-induced Caspase-1 maturation (Fig. 3.4 a), consistent
with preliminary data that d4T blocked Caspase-1 maturation in primary human RPE
cells (Fig. 3.1).
Utilizing a second system in which another NRTI, AZT, was rendered not
competent for phosphorylation, we tested whether AZT could block LPS/ATP-induced
inflammasome activation in thymidine kinase-deficient (Raji/TK-) cells, which do not
phosphorylate AZT 82. After addition of AZT, thymidine kinase-expressing (TK+)
parental cells, but not derivative TK- cells, produced AZT-triphosphate (AZT-TP), the
AZT metabolite required for RT inhibition (Fig. 3.5 b; Figs. 3.6-3.8). One consequence
of LPS/ATP-induced Caspase-1 activation is the proteolytic cleavage, maturation and
secretion of interleukin 1 beta (IL-1 beta). Even though AZT was not phosphorylated in
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TK- cells, AZT still inhibited LPS/ATP-induced interleukin-1 beta maturation (Fig 3.5 c),
indicating that AZT did not inhibit interleukin-1 beta maturation via RT inhibition.

	
  

39	
  

	
  

Figure 3.2 d4T blocks Alu-induced RPE degeneration and Caspase-1 activation
independent of reverse transcriptase inhibition
(A) Chemical structure of methoxy-d4T (me-d4T). A single substitution of the ribose 5’
hydroxyl group with a methoxy group (circled) designed to prevent d4T phosphorylation.
See Figures 3.3-3.5 for detailed synthesis information.
(B-C) Replication of a GFP-expressing lentivirus in HeLa cells was blocked by
unmodified d4T, but not me-d4T (100 µM both drugs). (B) Quantification of GFPpositive cells per field of view, n = 4, *p < 0.05 by Student’s t-test. (C) Representative
images.
(D) Unmodified d4T, but not me-d4T (100 µM both drugs), reduces mtDNA levels
(normalized to chromosomal DNA exon-intron junction sequence) in primary mouse
RPE cells as determined by real-time quantitative PCR. n=4, *p < 0.05 by Student’s ttest.
(E) Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells
transfected with Alu RNA + me-d4T (25 µM).
(F) Fundus photographs (top row) and flat mounts stained for zonula occludens-1 (ZO-1;
red) (bottom row) show that me-d4T (intraperitoneal injection) prevented Alu-induced
RPE degeneration in mice. In fundus photographs degeneration outlined by blue
arrowheads. Representative images of n = 4 (C, E, F) shown. Scale bars, (C): 200 µm;
(F): 20 µm. Fisher’s exact test p-value of (c) pAlu + vehicle vs. pAlu + me-d4T: 0.029.

	
  

40	
  

	
  

Figure 3.3 Synthesis of me-d4T
(A) Schematic overview of me-d4T synthesis.
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(B) HPLC chromatogram of me-d4T (peak # 6) final product, >97% purity.
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Figure 3.4 Synthesis of me-d4T
(A) 1H NMR spectroscopy of me-d4T final product, chemical shifts consistent with
structure.
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(B) Liquid chromatography/mass spectrometry of me-d4T final product, m/z ratio
consistent with structure.
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Figure 3.5 NRTIs block LPS/ATP-induced inflammasome activation
(A) Western blot of cell culture media (normalized to pro-Caspase-1 in cell lysate)
showing that d4T (100 µM) blocked Caspase-1 activation in LPS/ATP treated primary
mouse bone marrow-derived macrophages.
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(B) Liquid chromatography-mass spectrometry (LC-MS), showing that Raji TK+ cells,
but not Raji TK- cells, phosphorylate AZT (100 µM) to AZT-triphosphate (AZT-TP).
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(C) Western blot of cell lysates showing that AZT (100 µM) blocks IL-1 beta activation
by LPS/ATP in both Raji TK- and TK+cells. Representative images of n = 3-4
experiments (A-C).
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Figure 3.6 LC-MS/MS of AZT-TP and AZU-TP
LC-MS/MS spectra of AZT-triphosphate (AZT-TP, target compound; top) and AZUtriphosphate (AZU-TP, internal standard; bottom).
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Figure 3.7 AZT-TP and AZU-TP separation by liquid chromatography
Chromatographic separation of Raji TK- cells spiked with AZT-TP (top) and AZU-TP
(bottom) with MS spectra (insets) to confirm identity of designated peaks.
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Figure 3.8 AZT-TP formation in Raji TK+ cells
Standard curve of AZT-TP standards (black circle). Raji TK+ samples treated with AZT
(100 µM) produced AZT-TP (white triangles), whereas AZT-TP was not detectable in
Raji TK- cells treated with AZT. Representative of two experiments.
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3.4 Discussion
3.4.1 NRTI-induced mtDNA depletion
Phosphorylation of NRTIs is mediated by intracellular kinases. NRTItriphosphates (NRTI-TPs) are the active metabolites that prevent synthesis of an
elongating strand of complementary DNA because NRTI-TPs lack a 3’OH that is
required for addition of subsequent nucleotides by reverse transcriptase. As discussed in
Chapter 2, NRTI-TPs inhibit a range of enzymes besides reverse transcriptases, including
various host cell DNA polymerases.
Off-target effects of NRTIs in HIV patients are typically attributed to off-target
effects through inhibition of non-RT polymerases, in particular DNA polymerase gamma,
which is responsible for replicating mitochondrial DNA (mtDNA). In support of this
hypothesis, NRTIs have greater affinity for DNA polymerase gamma than other host
polymerases (section 3.1.2). Furthermore, mtDNA depletion occurs in symptomatic
tissues in patients taking NRTIs, and discontinuation of NRTIs leads to a rescue of
mtDNA abundance. This rescue of mtDNA levels correlates directly with resolution of
symptoms. Finally, molecular modeling studies also corroborate the DNA polymerase
gamma hypothesis of NRTI toxicity (reviewed in 93).
Although increased cytoplasmic levels of oxidized mtDNA can activate the
NLRP3 inflammasome 86, NRTI-induced reduction in mtDNA levels probably do not
account for the observed inflammasome inhibition for several reasons. For one, a version
of d4T (methoxy-d4T; Me-d4T) that did not affect mtDNA levels (unlike unmodified
d4T), but still blocked Alu-induced Caspase-1 activation in primary human RPE cells.
The lack of effect by Me-d4T on mtDNA levels is consistent with the methoxy
modification blocking phosphorylation; this result is also consistent with the finding that
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Me-d4T did not block lentivirus replication (Fig. 3.2). Furthermore, the time-course of
experiments is not long enough for NRTIs to exhibit considerable reductions in mtDNA.
For example, no considerable decrease in mtDNA is observed after 24 hours in Alu RNA
transfection experiments (Fig. 3.9 a), nor four hours after d4T exposure during the timecourse of LPS/ATP experiments (Fig. 3.9 b). In each experiment, cells were treated
exactly as in experiments to detect inflammasome activation by western blot (see
methods, Section 3.2.1). Finally, we found that several mtDNA-sparing NRTIs (3TC,
ABC) 89,90,93 block Alu-induced Caspase-1 activation, indicating that reduction of mtDNA
levels is not a common mediator of the protective anti-inflammatory class effect of
NRTIs. The use of Me-d4T, or other nucleoside analogs that exhibit little to no effect on
mtDNA levels, could be an effective therapeutic strategy to avoid off-target
mitochondrial effects.
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Figure 3.9. d4T does not affect total mtDNA levels over the time-course of
experiments. D4T treatment of primary human RPE cells A) transfected with Alu RNA
(t = 24 hrs) or B) after LPS (1000 ng/mL) treatment (t = 4 hrs) did not considerably alter
total mtDNA levels as detected by real-time quantitative PCR. n = 2, error bars represent
standard error.
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3.4.2

Reverse transcriptase-independent inhibition of NLRP3
inflammasome

In addition to showing that a phosphorylation-incompetent version of d4T
blocked inflammasome activation and RPE degeneration, we further ruled out reverse
transcriptase as a mechanism of NLRP3 inflammasome inhibition by NRTIs by showing
that d4T and AZT blocked IL-1 beta secretion by LPS/ATP, a stimulus which is not
known to signal through reverse transcriptase (Fig. 3.1). To show that AZT-triphosphate
does not mediate the inhibition of LPS/ATP-induced inflammasome activation, we used
the Raji TK-/+ B cell lymphoma cell line. Raji TK+ cells are the parental line from which
Raji TK- cells are derived via selection with 5-bromo-dUrd 94-96. We confirmed previous
reports that Raji TK- cells do not convert AZT to AZT-TP, whereas Raji TK+ cells do
(Fig. 3.1). In unpublished data, we also performed an experiment using 10 times the
numbers of Raji TK- cells as shown in Fig. 3.1, and still did not detect AZT-TP in TKcells by LC-MS. The great disparity in AZT-TP synthesis in these two Raji cell lines
suggests that AZT-TP does not mediate inhibition of IL-1 beta maturation after LPS/ATP
challenge.
Although B cells (e.g. Raji cells) are not a widely-used model system for NLRP3
inflammasome activation, we were able to detect mature IL-1 beta as a marker of
inflammasome activation in this system. There is precedent that B cells express (albeit
weakly) NLRP3, which can induce IL-1 beta maturation 97, and also that LPS/ATPinduces Caspase-1 activation in B-cells 98. The utility of this model beyond as a system
for interrogating RT inhibition-independent AZT function is not clear.
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3.4.3

Chromatographic separation of AZT and AZT-TP

We developed our own method for separating AZT and AZT-TP
chromatographically, based previous work by others 99. The details methodology of this
protocol can be found in Section 3.2.10 and in Figs. 3.6-3.8. Such a technique has major
implications for patients taking NRTIs in terms of optimizing dosing regimens, although
they have not yet been translated into clinical practice. The importance of separating AZT
and AZT-TP chromatographically is based in the idea that the conversion of NRTIs to
their NRTI-TP metabolite is thought to be a critical process in the blockade of HIV
replication 99. However, NRTIs have a relatively narrow therapeutic window, and the
adverse events due to NRTI toxicity are numerous, debilitating, and a major cause of
poor adherence to therapy, which leads to viral resistance to NRTIs 100. Currently, clinical
practice involves administering a fixed dose of NRTI based on an “over-under” weight
cut-off (60 kg), without regard to inter-individual differences in NRTI metabolism.
Therefore, optimization of a patient’s NRTI dose based on a direct measurement of NRTI
metabolism to NRTI-TP would help determine a best-practice dosing regimen (minimize
adverse effects while maximizing therapeutic efficacy).

3.4.4

IL-1 beta vs. IL-18 in AMD

In the Alu-induced model of RPE degeneration, we showed that IL-18, and not
IL-1 beta, was a key mediator of RPE degeneration 28. However, the role of IL-1 beta has
been shown as an effector in other models of NLRP3 activation in the RPE by other nonAlu stimuli (see section 2.4.1). Since Caspase-1 is required for the maturation of both IL18 and IL-1 beta, and because NRTIs function upstream of Caspase-1 to prevent IL-1
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beta maturation, we predict that NRTIs will also block other AMD models driven by the
NLRP3 inflammasome and IL-1 beta.
3.4.5

NLRP3 and HIV

The role of the NLRP3 inflammasome in driving or protecting against HIV
pathogenesis is not well defined, except for a few initial studies. Some have speculated
that HIV activation of the NLRP3 inflammasome is a protective effect that is lost in HIVinfected individuals, because HIV induces expression of NLRP3 and IL-1 beta secretion
from dendritic cells from HIV-infected individuals, but not healthy individuals 101. Others
have shown that HIV induces NLRP3 expression and IL-1 beta secretion from human
primary monocyte-derived macrophages 102. This hypothesis is based on findings that
NLRP3 activation is a guardian against infection by other viruses 103.
Whether NLRP3-dependent or not, a role for Caspase-1 in modulating against
HIV pathogenesis was recently described 104,105. In short, these papers showed that
Caspase-1 sensing of abortive HIV infections (i.e. incomplete HIV reverse transcripts in
the cytoplasm) in CD4+ T cells leads to their death. The authors of these works speculate
this seemingly protective response to clear infected cells might actually be undermined
by HIV, as the Caspase-1-induced inflammatory cell death recruits uninfected cells to the
locus of inflammation thereby enabling spread of the virus.
It is not known whether NRTIs modulate Caspase-1 activity in HIV. One clue
suggesting that NRTIs inhibit Caspase-1 activity is that HIV patients have increased
plasma IL-18 levels 106,107, which decrease after treatment with NRTI-containing highly
active anti-retroviral therapy 108. A possible mechanism could involve NRTI-mediated
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reduction of the number of abortive infections (as above), thereby dampening Caspase-1
activation.
However, given our findings, it will be important for future work to determine not
only whether NRTIs modulate Caspase-1 activation in HIV, but also whether such
inhibition is dependent on reverse transcriptase inhibition. Tools such as methoxy-d4T
and the Raji TK- cell system would be useful in answering this question. Interestingly,
reduction of plasma IL-18 levels by NRTI treatment of HIV-1 infected patients did not
significantly associate with viral load or CD4+ T-cell counts, consistent with the idea that
NRTIs can dampen IL-18 levels before inhibition of viral replication occurs 108.
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Chapter 4: NRTIs selectively block P2X7 pore function and P2X7-driven models of
graft rejection and sterile liver inflammation
4
4.1

Introduction

In Chapter 3 we established a proof-of-principle that d4T can inhibit the NLRP3
inflammasome without reverse transcriptase inhibition. The goal of the work in Chapter 4
is to gain a refined understanding of the mechanism of NRTI-mediated inflammasome
inhibition using d4T as the model inhibitor. Since NRTIs block Caspase-1 activation, we
looked at upstream mediators of inflammasome activity in the Alu model. Our efforts
focused on the cell-surface receptor P2X7, which is a common mediator of NLRP3
inflammasome activation by many stressors (see section 4.4).

4.2 Methods and materials
4.2.1 ATP assay
Primary human RPE cells were transfected as in section 2.2.1, in serum-free
DMEM. Cell culture supernatant was collected from cells, and centrifuged for 10 minutes
at 300 x g in order to remove cell debris. Supernatants were mixed with an ATPdependent luciferase reaction (Enliten ATP assay (Promega)), and fluorescence was
measured in a BioTek Synergy 4 plate reader, according to manufacturer’s instructions.
4.2.2

Cell-permeant and –impermeant d4T variants

Cell-permeant and –impermeant d4T variants were generously provided by Dr.
Keykavous Parang (University of Rhode Island) 109. See also Fig. 4.3 c-d.
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4.2.3

YO-PRO-1 assay

YO-PRO-1 iodide was purchased from Invitrogen. HEK293 cells stably
expressing the human P2X7 receptor (generously provided by George Dubyak, Case
Western Reserve University) were cultured in G418+ (400 µg/mL) DMEM with 10%
fetal bovine serum. Cells were trypsinized, and pellets were washed twice in 1x HBSS
(without calcium and magnesium). Resuspended cells were plated at 50 x 105 cells/well
on a 96 well black-walled cell culture plates spotted with A438079 or d4T to a
concentration 64 µM. Cells were incubated at 37 °C and 5% CO2 for 30 minutes before
addition of bzATP (100 µM) for 5 minutes, followed by YO-PRO-1 addition (2.5 µM)
after which plates were read immediately for fluorescence (485 ex/530 em) every 30
seconds for 5 minutes in a BioTek Synergy 4 plate reader.
4.2.4

Electrophysiology

Electrophysiology experiments were performed by collaborators Mark T. Young
and Marta Radwan (Cardiff University, Wales, U.K.). Whole-cell patch-clamp recordings
were made at room temperature using borosilicate glass pipettes (World Precision
Instruments, Sarasota, FL, USA) which had resistances of 3–5 MΩ when filled with a
solution containing the following (in mM): 145 NaCl, 10 EGTA and 10 HEPES, with the
pH adjusted to 7.3 with NaOH. The recording chamber was continually perfused with
extracellular saline solution (ECS) containing (in mM): 147 NaCl, 2 KCl, 1 MgCl2, 2
CaCl2, 10 HEPES and 13 glucose, with the pH adjusted to 7.3 with NaOH. To obtain
larger whole-cell currents by relieving divalent cation inhibition of P2X7 receptors
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mM ATP, 100 µM d4T and 1 mM ATP + 100 µM d4T were made in ECS with low
concentrations of divalent cations (ECS-LD) containing (in mM): 147 NaCl, 2 KCl, 0.2
CaCl2, 10 HEPES and 13 glucose, with the pH adjusted to 7.3 with NaOH . Current
recordings were made at a holding potential of −60 mV using an Axon Instruments
Axopatch Multiclamp 700A amplifier and Digidata 1322A A/D interface (Molecular
Devices, Sunnyvale, CA, USA). Agonist applications were made at 90-s intervals.
Compounds were applied to patch-clamped cells by means of a rapid perfusion system
(RSC-160, Biologic, Claix, France), allowing solution exchange times in the range 20–
100 ms.
4.2.5

Bone Marrow Transplant

Murine model of graft versus host disease was performed by collaborators Shoba
Amarnath and Daniel H. Fowler (National Institutes of Health, Bethesda, MD, U.S.A.).
Bone marrow (BM) cells from B6 mice were harvested and T-cell depleted (T-depleted;
anti-CD90 [Thy1.2] microbeads (Miltenyi Biotec). Host allogeneic recipients (BALB/c)
were conditioned with TBI of 950 cGy. BALB/c mice were rescued with 10M B6.Tdepleted BM (TDBM) cells alone or together with 2.5M bulk T cells (CD4+) from
B6.WT mice. Murine recipients that were reconstituted with TDBM and CD4+ T cells
were additionally treated for 10 days with either saline or stavudine (25 mg/kg/day) via
i.p injections; stavudine was initiated at either day -1 or day 0 of BMT, as indicated in
figure legend. Survival and clinical manifestations of GVHD were monitored.
4.2.6

Sterile liver inflammation model

Neutrophil migration in the sterile liver inflammation model was performed by
Keir Pittman and Paul Kubes at the University of Calgary (Calgary, Canada). Prior to
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each experiment, d4T (400 mg/kg) or control saline was administered via jugular vein
approximately 20 minutes prior to burn. Mice were anaesthetized with a solution
containing ketamine hydrochloride (200 mg/kg) and xylazine hydrochloride (10 mg/kg),
via intraperitoneal injection, per the University of Calgary Animal Use Protocol. The
jugular vein was exposed and canulated for administration of additional anaesthetic and
for administration of the compound or vehicle. Following administration of compound or
vehicle, a midline laparotomy was performed and a ~2.5 centimeter diameter section of
skin and peritoneum were removed from the ventral surface of the abdomen, exposing the
organs of the peritoneum. An electro-cautery probe fitted with a 30 gauge needle bent at a
90° angle was used to induce a single focal injury on the ventral surface of the left lobe of
the liver. Two hour recordings at 4x magnification were undertaken, using both green
(LysMeGFP+ cells) and red (autofluorescensce) channels (exposure times of 400 ms
respectively). Images were analyzed using ImageJ software and the number of GFP+
objects per field of view was determined as in 111.
4.2.7

Statistical analysis

Results are expressed as mean + standard error of the mean (SEM), with p values
< 0.05 considered statistically significant. Differences between groups were compared by
Mann-Whitney U test, Student’s t test, or two-way ANOVA with Student-Newman-Keul
post-hoc test, as appropriate, and two-tailed p values are reported. Survival analysis was
performed according to the Kaplan-Maier method and survival curves were compared
using log-rank test.
4.2.8
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MitoSox Red dye was obtained from Invitrogen and used according to the
manufacturer’s instructions. Briefly, MitoSOx Cells is a mitochondria-targeting
fluorogenic dye that is rapidly oxidized by superoxide but less so by other reactive
oxygen species. Upon oxidation MitoSOx binds to nucleic acids and fluoresces. Cells
were imaged 15 hours after Alu transfection, as described in section 2.2.1.
4.2.9

ELISA
Human interleukin-1 beta ELISA was purchased from R & D. Assay was

performed according to the manufacturer’s instructions.

4.3 Rationale and results
4.3.1 Alu RNA induces ATP release from human RPE cells
Alu RNA 30 and LPS/ATP 112 both activate the NLRP3 inflammasome via the
ATP receptor P2X7. We therefore hypothesized that d4T blocks P2X7 or a P2X7dependent pathway. First, we tested whether d4T acted upstream of P2X7 by modulating
ATP release from cells. To test this idea, we measured ATP in serum-free media after
transfection of primary human RPE cells with Alu RNA using an ATP-dependent
luciferase reaction kit (section 4.2.1). ATP levels peaked at 4 and 6 hours after Alu RNA
transfection, however, d4T did not block this extracellular release of ATP induced by Alu
RNA (Fig. 4.1 a).
4.3.2

d4T does not affect P2X7 channel function

Since d4T did not affect ATP release, we hypothesized that d4T worked just
downstream of this event to directly antagonize P2X7 function. There are two well
described functions for P2X7 upon ATP binding, both of which are linked to NLRP3
inflammasome activation: 1) Non-selective cation channel flux directly through P2X7;
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and 2) Pore function, or increased cell permeability to large molecules up to ~1000 Da
(nomenclature is confusing, as “pore” is typically used to define ion flux; however, in this
case, the term “pore” will be used instead, consistent with the literature, to refer to this
increased cell permeability to large molecules).
Since P2X7 is a non-selective cation channel, its activation leads to potassium
efflux from the cell. Potassium efflux has been suggested as a common mechanism of
multiple NLRP3 inflammasome stressors 113-115, 116. However, d4T did not affect cation
flux (Fig. 4.1 b-c) as monitored by whole-cell patch clamp analysis of HEK293 cells
transiently transfected with either the human or rat P2X7 receptor upon ATP stimulation
(Fig. 4.1 b-c; experiments performed by M. Radwan and M. Young, Cardiff University,
United Kingdom), indicating that d4T does not inhibit Alu-induced inflammasome
activation via modulation of P2X7-mediated potassium flux.
4.3.3

d4T blocks P2X7-dependent dye uptake

P2X7 activation is also associated with the formation of a large pore that is
permeable to molecules of up to ~ 1,000 Da 117-119. The rapid (within seconds) uptake of
large dyes, such as YO-PRO-1 iodide, is a gold standard assay for P2X7 activation. The
relevance of dye uptake to inflammasome activation is not clear; dye uptake may simply
be a marker of P2X7 function. Although the link between dye uptake and inflammasome
requires further elucidation, we implicate interference with P2X7-mediated dye uptake as
a mechanism of blocking Alu-induced inflammasome activation.
YO-PRO-1 is a dye that fluoresces upon nucleic acid binding; an increase in
fluorescences occurs upon YO-PRO-1 entry into cells, where it binds nucleic acids. We
found that d4T and the known P2X7 antagonist A438079 inhibited rapid P2X7-
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dependent uptake of the fluorescent dye YO-PRO-1 iodide (M.W. 629 Da) in a human
P2X7-overexpressing HEK293 stable cell line (Fig. 4.1 d) after addition of a benzoylated
version of ATP (bzATP) that is a highly selective agonist for P2X7. Non-P2X7
expressing HEK293 cells (Fig. 4.2) did not exhibit bzATP-induced YO-PRO-1 dye
uptake as measured by fluorescence.
4.3.4

Selective P2X7-dependent pore antagonism blocks Alu-induced
inflammasome activation

Interestingly, d4T only partially inhibited YO-PRO-1 uptake compared to
A438079, whereas Alu RNA-induced Caspase-1 activation was completely blocked by a
small peptide targeting the P2X7-associated Pannexin-1 channel, which inhibits P2X7dependent dye uptake and LPS/ATP-induced inflammasome activation, but not cation
flux 120 (Fig. 4.3 a). These data are consistent with the idea that P2X7 activation leads to
activation of multiple cell permeabilization pathways 121, and that inhibition of some but
not all of these pathways by d4T is sufficient to fully block Caspase-1 activation.
Conversely, Alu RNA-induced Caspase-1 activation was not inhibited by calmidazolium,
which selectively blocks P2X7-mediated cation flux but not dye uptake (Fig. 4.3 b). This
result is consistent with the idea that inhibition of P2X7-dependent pore function by d4T,
and not cation channel modulation, is responsible for the protective effects of d4T in Alu
RNA-induced inflammasome activation.
4.3.5

d4T requires cell entry to block Alu-induced inflammasome activation

There are many lines of evidence indicating that the intracellular C-terminus of
P2X7 selectively governs dye uptake function, and is not or is less essential for
modulating P2X7 cation function. For one, deletion of the last 177 (C-terminal) amino
acids in P2X7 abrogates dye uptake without affecting cation channel function 117,122.
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Numerous other deletions and point mutations in C-terminal intracellular domains of
P2X7 abrogate pore formation; some of these disruptions alter cell-surface expression
and cation function, but in others these characteristics are maintained 123-125, therefore
implicating the C-terminus of P2X7 as a key regulator of P2X7 dye uptake function. We
hypothesized that if d4T requires cell entry to block Caspase-1 cleavage, then this would
be consistent with the idea that d4T modulates P2X7 C-terminus function. Indeed, a
version of d4T that is not cell permeable 109 did not block Caspase-1 activation by Alu
RNA in primary human RPE cells, whereas a version of d4T that readily permeates cells
very effectively blocked Caspase-1 activation (Fig. 4.3 c-d).
4.3.6

d4T blocks Alu-induced mitochondrial ROS

Consistent with antagonism downstream of P2X7 but preceding inflammasome
activation, d4T blocked Alu-induced mitochondrial ROS (mtROS) production 28 as
measured by MitoSOx assay (Fig. 4.3 e; method detailed in Section 4.2.8).
4.3.7

d4T does not block MSU-induced IL-1 beta secretion

We hypothesized that if d4T antagonizes P2X7, then it would not prevent P2X7independent inflammasome activation. Previous work showed that crystalline
monosodium urate (MSU) causes interleukin 1-beta secretion independent of P2X7
126,127

. Following the same methodology from previous work, we treated THP-1

monocytes with phorbol 12-myristate 13-acetate (PMA) overnight in order to
differentiate them into macrophages. We treated these PMA-primed THP-1 cells with
MSU, and measured IL-1 beta secretion to the cell culture supernatant by ELISA: we
found that d4T did not significantly inhibit IL-1 beta secretion (Fig. 4.4) at a wide dose
range of d4T. Collectively, these data indicate that d4T blocks P2X7-dependent
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inflammasome activation via a mechanism involving selective inhibition of P2X7associated pore function.
4.3.8

d4T is efficacious in a murine model of graft-versus-host-disease

To explore the potential therapeutic relevance of NRTIs beyond the Alu RNAinduced model of GA, we hypothesized that if NRTIs function as NLRP3 inflammasome
inhibitors then they might be broadly useful in other animal models of disease that are
also driven by P2X7. Murine graft-versus-host disease (GVHD) is NLRP3
inflammasome- and P2X7-driven 128,129; consistent with these results, treatment of
allogeneic bone marrow and T cell recipients (donor: C57Bl6 mice; recipient BALB/c)
with d4T improved survival compared to saline treated controls (Fig. 4.1 e).
Intraperitoneal administration of d4T starting one day before bone marrow transplant
showed superior survival (70% vs. 0% (saline)) compared to d4T beginning on the day of
transplant (30% vs. 0% (saline)), consistent with findings that inflammasome activation
occurs very early on and dictates the development and severity of GVHD 128,129.
4.3.9

d4T modulates neutrophil migration in a sterile liver injury model

Finally, we tested the efficacy of d4T in a model of sterile liver injury, which was
previously shown to be dependent on NLRP3 and P2X7 111. In this model, a sterile, focal
injury is performed by needle poke of the liver. The experiment is performed in LysMGFP+ mice, which express GFP under the control of the lysozyme M promoter, which is
expressed at very high levels by neutrophils, and to a lesser degree macrophages and
monocytes130. Neutrophils (GFP+ cells) are the primary cell type to invade the focus of
injury within the first few hours. A bolus of intravenous d4T was delivered starting about
half an hour before liver injury and reduced early neutrophil migration to the focus of
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liver injury (Fig. 4.1 f; Fig. 4.4). Again, this finding is consistent with the idea that d4T
antagonizes P2X7 signaling.
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Figure 4.1 NRTIs selectively block P2X7 pore function and P2X7-driven models of
graft rejection and sterile liver inflammation
(A) d4T (100 µM) does not block Alu-induced ATP release from primary human RPE
cells (n = 4).
(B-C) Experiments performed by M. Radwan and M. Young (Cardiff University, United
Kingdom). Whole-cell patch clamp of rat and mouse P2X7 receptors in HEK293 cells.
Cells were pre-incubated in d4T for at least 1 minute prior to application of 1 mM ATP
(also in the presence of d4T). Currents were recorded in solutions containing low
concentrations of divalent cations (giving larger currents but causing delayed return of
current to baseline after washout). (B) Histogram showing the mean current density
recorded for rat P2X7 and mouse P2X7 in the absence (-) and presence (+) of 100 µM
d4T. Error bars represent standard error of the mean (n = 6 for rat P2X7 and n = 3 for
mouse P2X7). No significant difference to recorded currents was observed in the
presence of d4T. (C) Representative current traces from rat P2X7 in the absence (red) and
presence (black) and mouse P2X7 in the absence (blue) and presence (grey) of 100 µM
d4T.
(D) P2X7-mediated YO-PRO-1 dye uptake induced by bzATP (100 µM) in HEK293
cells stably expressing the human P2X7 receptor was inhibited by d4T and A438079 (64
µM for both drugs). Fluorescence values are baseline subtracted from cells without
bzATP treatment. * bzATP vs. d4T; # bzATP vs. A438079, p < 0.05 by Student-Newman
Keuls post-hoc test (n = 12).
(E) Administration of Stavudine Starting From Day -1 Pre-transplant Protects Murine
Recipients from Graft versus Host Disease. BALB/c mice were subjected to TBI
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(950cGY) and then reconstituted with T depleted bone marrow (TDBM) from B6 donors.
Cohorts (n = 10 per cohort) received either BM alone or BM plus bulk CD4+ T cells
(2.5M) on the same day as the irradiation. Cohorts that received BM and bulk CD4+ T
cells were additionally treated with either vehicle (saline) or drug (stavudine) from day -1
or day 0 for a period of 10 days. Clinical manifestations of GVHD and overall survival
were monitored post-BMT. Survival analysis was performed according to the KaplanMaier method and survival between groups was compared using the log-rank test. Results
were pooled from two independent experiments. Experiment performed by Shoba
Amarnath (NIH).
(F) d4T (400 mg/kg) inhibits P2X7-dependent neutrophil recruitment to sites of focal
hepatic necrosis. n = 4, error bars S.E.M., p < 0.05 by Student-Newman Keuls post-hoc
test. Experiment performed by Keir Pittman (University of Calgary).
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Figure 4.2 bzATP induces P2X7-dependent YO-PRO-1 uptake
(A) Western blot for P2X7 in HEK293 cells vs. HEK293 cells stably expressing the
human P2X7 receptor.
(B) bzATP did not induce YO-PRO-1 uptake in P2X7-deficient HEK293 cell. n= 2-3,
representative of two independent experiments.
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Figure 4.3 P2X7-dependent pore function mediates Alu-induced Caspase-1
activation
(A-C) Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells
transfected with Alu RNA + (A) Short peptide (Panx110; 240 µM) that blocks P2X7 pore
function but not cation flux (vs. scrambled peptide: Scr Panx110; 240 µM); (B)
Calmidazolium, which blocks P2X7 cation flux but not pore function, did not block
Caspase-1 activation induced by Alu RNA.
(C) Western blot showing that cell permeable (IC) and unmodified (no tag) d4T, but not
cell-impermeable (EC), blocked Caspase-1 activation (p20 subunit) induced by Alu RNA.
All drugs administered at 100 µM. Representative of n = 3 experiments.
(D) Chemical structure of IC- and EC-d4T used in (C).
(E) Mitochondrial ROS visualized with MitoSox (Red) and cell nuclei with Hoechst
(Blue), showing that d4T (100 µM) prevents pAlu-induced mitochondrial ROS
generation in primary human RPE cells. Representative image of n = 3-4.
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Figure 4.4 d4T does not inhibit MSU-induced IL-1 beta secretion
ELISA of cell culture supernatants in PMA-primed THP-1 cells shows that d4T does not
block MSU-induced IL-1 beta secretion (n = 3-4).

Figure 4.5 d4T inhibits neutrophil chemotaxis after acute liver injury
LysMeGFP cells/FOV around a sterile focal hepatic lesion. D4T (400 mg/kg) or PBS
administered via jugular vein 20 minutes prior to injury. n = 4, error bars S.E.M., p <
0.001 between groups vehicle vs. d4T by two-way ANOVA. Experiment performed by
Keir Pittman (University of Calgary).
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4.4 Discussion
4.4.1 The role of P2X7 and ATP in Alu-induced inflammasome activation
We suspected that d4T antagonized P2X7 or P2X7 signaling because previously
we found that P2X7 is a critical mediator of Alu RNA toxicity 30. Also, the link between
P2X7 as an upstream mediator of the inflammasome is well described, especially in terms
of LPS/ATP activation of the inflammasome 112, which was blocked by NRTIs (Fig. 3.1).
Canonically, P2X7 functions as an ATP receptor. Here we confirmed that Alu RNA
indeed signals through ATP to induce Caspase-1 activation. Preliminary time-course
experiments from 1-24 hrs revealed that ATP levels in cell culture media peaked at 4 and
6 hours after Alu RNA transfection. However, d4T did not affect ATP release induced by
Alu RNA (Fig. 4.1 a), indicating that it functions somewhere downstream of ATP to
block Caspase-1 activation. It would be interesting to test whether other nucleoside
analogs also block P2X7 function in terms of dye uptake or other P2X7-mediated
functions. All NRTIs need not block Caspase-1 cleavage by the same mechanism.
We showed that d4T antagonizes P2X7 function by blocking YO-PRO-1 dye uptake;
whether d4T acts directly at P2X7 or targets a P2X7-interacting protein remains to be
determined (see discussion in section 4.4.2). P2X7 heteromerizes with another ATP
receptor, P2X4, to form functional complexes 131 ; future work could determine whether
there is any role for P2X4 in mediating P2X7-dependent Alu-induced RPE degeneration.
We also showed that a mimetic peptide targeting Pannexin-1 has a protective
effect in the Alu-induced model of inflammasome activation. Further work will also be
required to confirm the relevance of Pannexin-1 in the Alu-induced model. This work is
especially important in consideration of the fact that pannexin-1 targeting by mimetic
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peptide and siRNA knockdown protects against LPS/ATP-induced inflammasome
activation 120, whereas there is no protective effect from LPS/ATP in cells genetically
deficient for P2X7 112. Such future approaches should include testing whether Alu RNA
induces toxicity in Pannexin-1 knockout mice or after siRNA knockdown.
4.4.2

P2X7 C-terminus and dye uptake

The C-terminal tail of P2X7 contains multiple putative phosphorylation sites for
cellular kinases, suggesting that such modifications could affect P2X7 receptor
function/localization 123; others have shown that tyrosine phosphorylation of other
proteins in the P2X7-interactome negatively regulate P2X7 function 132. Still other work
shows that P2X7 activation results in its dephosphorylation 133, which affects interaction
with its binding partners, including many cytoskeletal proteins. Signal transduction along
microtubule rearrangement is a known mediator of NLRP3 inflammasome activation 134;
it is tempting to speculate that the activity of d4T, and other NRTIs, could intersect with
these signaling pathways. Another interesting future direction would be to investigate the
possibility that NRTIs, which are well-described kinase substrates, act as “dummy”
substrates or act as kinase sinks to alter the intracellular kinome.
4.4.3

Binding studies of d4T and P2X7

There is considerable structural diversity of P2X7 antagonists 132, and common
motifs or patterns that characterize P2X7 antagonism are not well defined. It is unclear if
these antagonists bind directly to P2X7, an issue that remained unresolved in part due to
the lack of a published P2X7 crystal structure. Although the P2X7 receptor has not been
crystallized, it has been modeled based on homology with the crystal structure P2X4
zebrafish 135,136. Future bioinformatics analyses could use this model to predict NRTI
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binding to P2X7. The residues critical for nucleotide binding by P2X7 have been
described, including the key residues involved in ATP binding 135,137. Interestingly,
although ADP does not bind P2X7, a ribosylated version of ADP does covalently bind
and activate P2X7 138-140. This ATP-independent P2X7 activation is mediated by
extracellular NAD+ (which is converted to ADP-ribose). It is tempting to speculate that
multiple NRTIs could modulate P2X7 receptor activation by virtue of their common
ribose motif.
We were unsuccessful in two binding assays to show interaction of d4T with
P2X7. First, we attempted to detect binding of carboxyfluorescein-conjugated d4T to
recombinant full-length P2X7 protein (Novus Biologicals). Several limitations could
explain why no binding was detected by this approach. For one, the protein was purified
from an in vitro wheat germ expression system; perhaps requires d4T interaction with
P2X7 requires mammalian-specific post-translational modifications. Another possibility
is that the carboxyfluorescein tag could have altered d4T binding. We were also
unsuccessful in our attempt to detect interaction by incubating P2X7 immunoprecipitate
with fluorescent-conjugated d4T. This approach, as with attempt with the recombinant
P2X7 binding study, is limited by the fact that P2X7 forms homotrimeric membrane
complexes, in addition to complexes with other P2 receptors (i.e. P2X4) 131. These
complexes could have been disrupted or altered during protein extraction (second
approach), or would not have been present (first approach). Attempts could be made to
preserve these interactions, for example using purified membrane preparations 141.
Alternative approaches for future investigation might include or combine techniques such
as surface plasmon resonance, a “grind-and-bind” approach using whole cell lysates, in
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situ imaging of labeled d4T comparing P2X7-overexpressing vs. –deficient cells, and
using radiolabeled-d4T to overcome potential steric obstruction of binding by fluorescent
tag molecule. Even if d4T or other NRTIs do not bind to P2X7, future work could also
investigate whether d4T modulates P2X7 activity by altering its sub-cellular localization
or trafficking 123,124,142. P2X7 is expressed in the RPE 143,144; future work could determine
whether P2X7 levels are altered in AMD.
4.4.4

NRTI function beyond the Alu RNA model

To our knowledge, until now there have not been any reports of FDA-approved
drugs that selectively target P2X7 dye uptake function without affecting cation channel.
Interestingly, selective P2X7 pore inhibition (without cation flux modulation) was found
to reduce a mouse model of neuropathic pain 145. This finding suggests that d4T (and
possibly the other NRTIs tested herein) could be ideal drug repurposing candidates for
neuropathic pain (or, in the future, other P2X7 pore-selective-pathies). Unfortunately,
d4T is shown to induce pain in rodent models 146,147; however, even if d4T is not ideal
candidate for selective P2X7 targeting in pain, other NRTIs that are not associated with
pain induction in humans/animal models could be explored as potential therapeutics via
P2X7 blockade.
The extension of our work to animal models of graft-versus-host disease and
neutrophil migration not only broadens the appeal and utility NRTI drug repurposing, but
also promises to lend insight into the mechanism of anti-inflammatory NRTI function.
The GVHD and neutrophil migration models exhibit overlapping mechanisms with the
Alu-induced model, in that they are all mediated by ATP, P2X7 and NLRP3. Future
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investigations could focus on the role of P2X7 pore function in these models to shed light
on the mechanism of d4T on P2X7-dependent signaling.
We showed that d4T had a dramatic protective effect on the mouse survival in an
allogeneic bone marrow transplant graft-versus-host disease model (Fig. 4.1 e). Graftversus host disease is the major obstacle preventing successful tissue transplant 148,149.
P2X7 also drives heart transplant rejection in humans and mice 150; however, for the most
part, a therapeutic role for P2X7 inhibition in other transplant models remains to be
determined.
D4T also affected neutrophil migration to a focus of injury in a model of sterile
liver inflammation, which is a major contributor to drug-induced liver injury and
steatohepatitis, a major determinant of fibrosis and carcinogenesis 151; future work could
determine the physiologic or pathologic ramifications of NRTI modulation of innate
immune cell chemotaxis and function.

4.4.5

P2X7 and HIV replication

There is some evidence that P2X7 facilitates HIV replication 152. Therefore, our
finding that NRTIs inhibit P2X7 should lead to a re-examination of the mechanistic basis
of NRTI function in HIV therapy. Could the therapeutic response induced by NRTIs in
HIV patients be explained in part by P2X7 inhibition? Methoxy-d4T would be an ideal
tool to probe the relative contributions of reverse transcriptase inhibition vs. P2X7
blockade in HIV replication. Since methoxy-d4T is not phosphorylated and therefore
does not affect mitochondrial DNA levels, its use as an adjuvant in HIV patients would
allow for P2X7 inhibition without the side effects attributable to inhibition of
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mitochondrial DNA synthesis (see section 3.4.1). One could also probe the role of P2X7
inhibitory activity of NRTIs in the absence of RT inhibition by testing whether AZT
inhibits the replication of HIV (or other retroviruses with tropism for B cells) in Raji TKcells 153.
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Conclusion
NRTIs are a diverse, widely used, inexpensive class of small molecules, with
extensive pharmacokinetic and safety data collected over several decades of human use.
Our work, by illustrating a novel mechanism of action of NRTIs, paves a clear path for
the broad repurposing of this drug class to address major unmet medical needs: agerelated macular degeneration is a disease that affects tens of millions of people
worldwide for which there is no effective treatment 1,154. Since inflammasome inhibition
by NRTIs can be achieved without their phosphorylation, the use of me-d4T or other
phosphorylation-incompetent nucleoside analogs to treat these diseases could avoid doselimiting toxicities associated with NRTI-triphosphate-mediated polymerase inhibition 55.
Systemic side effects of NRTIs could also be avoided by local administration of NRTIs
(i.e. intra-ocular injection or sustained-release ocular implant for AMD). Furthermore, as
AMD is a disease that typically progresses slowly (over years), low-doses of oral
administration may be therapeutic without dose-limiting side effects. It is not known
whether chronic NRTI use is protective against developing AMD; however, as the
population of aging HIV-positive individuals continues to grow, it might be possible to
determine this predicted effect.
Graft-versus host disease is the major obstacle preventing successful allogeneic
hematopoietic stem cell transplantation 148. Also, neutrophil migration is a major
contributor to drug-induced liver injury and steatohepatitis, which in turn is a major
determinant of fibrosis and carcinogenesis 151. Future work should determine the
physiologic or pathologic ramifications of NRTI modulation of innate immune cell
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chemotaxis and function in a variety of disease models. Adverse effects associated with
long-term NRTI use would be avoided with short-term NRTI use in acute conditions (i.e.
acute GVHD or exacerbation of other inflammatory disease).
A role for P2X7 in regulating HIV replication was recently proposed 152; of note,
HIV patients have increased plasma levels of the inflammasome effector IL-18 106,107,
which decrease after treatment with NRTI-containing highly active anti-retroviral therapy
108

. Interestingly, reduction of plasma IL-18 levels by NRTI treatment of HIV-1 infected

patients was not significantly associated with viral load or CD4+ T-cell counts, thereby
indicating that NRTIs can dampen IL-18 levels before inhibition of viral replication
occurs. IL-18 maturation requires pro-IL18 cleavage by active Caspase-1, which typically
also requires P2X7 activation. Thus, future work could address whether NRTIs can
modulate HIV-induced cytokine expression/viral replication independent of reverse
transcriptase inhibition.
Interestingly, it has been reported that P2X7-dependent pore function alone can
influence phenotype 145. However, to our knowledge, there are no FDA-approved drugs
that selectively target P2X7 signaling and not ion channel activation. Therefore, NRTIs
could be valuable clinically and experimentally in the selective targeting of P2X7
function.
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Appendix

Sequence of Alu sequence used for synthesis of in vitro transcribed Alu RNA (in pUC18
plasmid, gift of J. Goodrich). DraI cut site on plasmid is annotated at position 308.

Sequence of Alu sequence in pAluA (in pUC19 plasmid, gift of J. Moran).

1

10

|

|

20
|

30
|

40
|

50

|

GGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTT
CGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCG
GAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCT
TTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCT
GTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAG
CCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCC
CAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGC
TGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAAT
TAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGC
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TTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACA
GGAAACAGCTATGACCATGATTACGCCAAGCTTGGGCTGCAGGTCGACTC
TAGAGGATCCCCCCCCCCCGCTCCCCAATGACGTAACTGCCCTGCAGCTT
CTAGTAGCTTTTCGCAGCGTCTCCGACCGGCCGGGCGCGGTGGCTCACGC
GTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAG
GAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAA
AAAAAATACAAAAAATTAGCCGGGCGTGGTAGCGGGCGCCTGTAGTCCCA
GCTACTCGGGAGGCTGAGGCAGGGGAATGGCGTGAACCCGGGAGGCGGAG
CTTGCAGTGAGCCGAGATCCCGCCACTGCACTCCAGCCTGGGCGACAGAG
CGAGACTCCGTCTCAAATCCCCTCAGAAGAACTCGTCAAGAAGGCGATAG
AAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAA
GCGGTCAGCCCATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCA
ACGCTATGTCCTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATG
AATCCAGAAAAGCGGCCATTCTCCACCATGATATTCGGCAAGCAGGCATC
GCCATGGGTCACGACGAGATCCTCGCCGTCGGGCATGCGCGCCTTGAGCC
TGGCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCA
TCCTGATCGACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCG
ATGTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCA
GCCGCCGCATTGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGG
TGAGATGACAGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAGCCAGTC
CCTTCCCGCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCCCG
TCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCCTGTAATTAGCAATAT
AATGAATTGCAGGGAAAAGTTATCAGGCATGCACCTGGTAGCTAGTCTTT
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AAACCAATAGATTGCATCGGTTTAAAAGGCAAGACCGTCAAATTGCGGGA
AAGGGGTCAACAGCCGTTCAGTACCAAGTCTCAGGGGAAACTTTGAGATG
GCCTTGCAAAGGGTATGGTAATAAGCTGACGGACATGGTCCTAACCACGC
AGCCAAGTCCTAAGTCAACAGATCTTCTGTTGATATGGATGCAGTTCACA
GACTAAATGTCGGTCGGGGAAGATGTATTCTTCTCATAAGATATAGTCGG
ACCTCTCCTTAATGGGAGCTAGCGGATGAAGTGATGCAACACTGGAGCCG
CTGGGACCTAATTTGTATGCGAAAGTATATTGATTAGGTTTGGAGTACTC
GAGTTCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAAAGAACCGGGC
GCCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCCGATTGTC
TGTTGTGCCCAGTCATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGA
ACCTGCGTGCAATCCATCTTGTTCAATGGCCGATCCCATATTGGCTCGAC
CTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCG
GCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGA
ATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCG
GGACTATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCT
GCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACC
CTAACTGACACACATTCCACAGCCGTCTCAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAACATGGGACTCAAAGTTTCAGCATCGCG
TCTCTTTTGCCGAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGA
AAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCG
CCAGCTGGCGTAATAGCG
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Annotations:

Name
7SL/Promoter
AluA
AluA_End
Cloning/Vector
CloningVector
M13F
M13R
NeoResistance
puc19
puc19

	
  

Start

End
563
629
2473
532
2524
2568
499
918
1
2563
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Length
628
917
2523
562
2562
2584
515
2472
531
2668

66
289
51
31
39
17
17
1555
531
106
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